This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/030757-2024">https://www.find-tender.service.gov.uk/Notice/030757-2024</a>

#### Contract

# **National Child Parent Screening Service Evaluation**

Health Innovation North East and North Cumbria

F03: Contract award notice

Notice identifier: 2024/S 000-030757

Procurement identifier (OCID): ocds-h6vhtk-03cfc6

Published 26 September 2024, 11:55am

# **Section I: Contracting authority**

### I.1) Name and addresses

Health Innovation North East and North Cumbria

Suite A, 2nd Floor, 1 Citygate, Gallowgate

Newcastle-upon-Tyne

NE14WH

#### **Email**

Business Development @healthinnovationnenc.org.uk

### **Telephone**

+44 1916076350

### Country

**United Kingdom** 

# Region code

UK - United Kingdom

# Internet address(es)

Main address

https://healthinnovationnenc.org.uk/

Buyer's address

https://healthinnovationnenc.org.uk/

# I.4) Type of the contracting authority

Other type

CLG

# I.5) Main activity

Health

# **Section II: Object**

### II.1) Scope of the procurement

### II.1.1) Title

National Child Parent Screening Service Evaluation

Reference number

DN736345

#### II.1.2) Main CPV code

• 79419000 - Evaluation consultancy services

#### II.1.3) Type of contract

Services

#### II.1.4) Short description

Funding was received by Health Innovation North East and North Cumbria (HI NENC) in April 2021 to implement and lead on the national Child Parent Screening Programme. This was in order to support the ambition set out in the NHS Long Term Plan to improve the identification of Familial Hypercholesterolaemia (FH) to 25% by 2025.

Previously, HI NENC had embarked on a programme of work to search primary care records for those at risk of FH. Alone this was unlikely to achieve the NHS LTP ambition - the addition of a child-parent screening (CPS) programme was introduced to help increase identification of FH patients and their families.

FH, an autosomal dominant inherited disorder, is a common cause of ischaemic cardiovascular disease in young adult life. There are about 200,000 undiagnosed people with FH in the UK. Identifying affected individuals before the onset of disease is important so diet and lifestyle modifications can be made and medication initiated as appropriate.

As each affected child will have one affected parent, testing children provides a means of identifying and treating both child and parent together in a systematic manner.

This project aims to evaluate the effectiveness of the implementation of the child parent screening service as well as the impact it has had. A mixed methods approach will be used drawing on a variety of techniques.

#### II.1.6) Information about lots

This contract is divided into lots: No

### II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £39,850

## II.2) Description

#### II.2.2) Additional CPV code(s)

- 73000000 Research and development services and related consultancy services
- 79419000 Evaluation consultancy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

Funding was received by Health Innovation North East and North Cumbria (HI NENC) in April 2021 to implement and lead on the national Child Parent Screening Programme. This was in order to support the ambition set out in the NHS Long Term Plan to improve the identification of Familial Hypercholesterolaemia (FH) to 25% by 2025.

Previously, HI NENC had embarked on a programme of work to search primary care records for those at risk of FH. Alone this was unlikely to achieve the NHS LTP ambition - the addition of a child-parent screening (CPS) programme was introduced to help increase identification of FH patients and their families.

FH, an autosomal dominant inherited disorder, is a common cause of ischaemic cardiovascular disease in young adult life. There are about 200,000 undiagnosed people with FH in the UK. Identifying affected individuals before the onset of disease is important so diet and lifestyle modifications can be made and medication initiated as appropriate.

As each affected child will have one affected parent, testing children provides a means of identifying and treating both child and parent together in a systematic manner.

This project aims to evaluate the effectiveness of the implementation of the child parent

screening service as well as the impact it has had. A mixed methods approach will be used drawing on a variety of techniques.

#### II.2.5) Award criteria

Quality criterion - Name: Technical/Quality / Weighting: 70

Quality criterion - Name: Social Value / Weighting: 10

Price - Weighting: 20

### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# **Section IV. Procedure**

# IV.1) Description

### IV.1.1) Type of procedure

Restricted procedure

## IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

# IV.2) Administrative information

### IV.2.1) Previous publication concerning this procedure

Notice number: <u>2023/S 000-015073</u>

# Section V. Award of contract

#### Lot No

3

#### Title

National Child Parent Screening Service Evaluation

A contract/lot is awarded: Yes

### V.2) Award of contract

### V.2.1) Date of conclusion of the contract

24 September 2024

### V.2.2) Information about tenders

Number of tenders received: 4

The contract has been awarded to a group of economic operators: No

# V.2.3) Name and address of the contractor

Health Innovation North East and North Cumbria

Suite A, 2nd Floor, 1 Citygate, Gallowgate

Newcastle-upon-Tyne

NE14WH

**Email** 

BusinessDevelopment@healthinnovationnenc.org.uk

Telephone

+44 1916076350

Country

**United Kingdom** 

**NUTS** code

• UK - United Kingdom

The contractor is an SME

Yes

# V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £39,850

# **Section VI. Complementary information**

# VI.4) Procedures for review

# VI.4.1) Review body

Health Innovation North East and North Cumbria

Newcastle-upon-Tyne

Country

**United Kingdom**